The Startup That Promised Too Much

Theranos promised to run a wide range of blood tests from a few drops of blood from a finger prick, cheaply and quickly, at your local pharmacy. Its founder, Elizabeth Holmes, started it in 2003 and soon dropped out of Stanford to run it. At its peak, Theranos was valued at about $9 billion, with a board of famous names.

The problem: the technology didn't work as claimed. By 2018 the company was dissolving, and in 2022 Holmes was convicted of defrauding investors. Theranos is now the standard cautionary tale of "fake it till you make it" in a field where it can hurt people.

🎯 Quick Answer (30-Second Read)

  • The claim: many tests from a finger-prick sample on its own "Edison" device.
  • The reality: the device couldn't reliably do this; many tests were run on modified commercial machines, and results were often inaccurate.
  • Exposed by the Wall Street Journal reporter John Carreyrou in October 2015, helped by employee whistleblowers.
  • Regulators found serious problems in its lab; Walgreens ended its partnership.
  • 2022: Holmes was convicted on four counts of defrauding investors and sentenced to more than 11 years in prison. Former president Ramesh "Sunny" Balwani was convicted on all 12 counts he faced.

The Timeline

timeline title Theranos 2003 : Founded by Elizabeth Holmes 2013 : Walgreens partnership launches wellness centres 2014 : Valued at about $9 billion 2015 : WSJ investigation published (October) 2016 : Regulators sanction its lab 2018 : SEC fraud charges, company dissolves 2022 : Holmes convicted (January), sentenced (November)

What Theranos Claimed vs Reality

Claim Reality (as reported and found in court)
Hundreds of tests from a finger prick The Edison ran only a limited number of tests and wasn't reliable
Proprietary technology did the testing Many tests ran on modified third-party analysers
Results were accurate Inaccurate results reached patients; many were later voided
Validated by major partners Demonstrations and claims misled investors and partners

Why the Science Was Hard

Tiny samples
Finger-prick blood is a very small volume, and many tests need more to be accurate.
Contamination
Squeezing a finger mixes in tissue fluid, which can distort results compared with blood drawn from a vein.
Dilution
Stretching a small sample across many tests means diluting it, which reduces accuracy.

These aren't problems a better pitch deck can solve. Medical testing has to be validated, and errors directly affect patients' treatment.

How It Lasted So Long

flowchart LR S["Secrecy
(trade secrets, NDAs)"] --> NC["No outside
scientific checks"] B["Famous board,
little lab expertise"] --> NC I["Investors trusting
reputation, not data"] --> NC NC --> V["Valuation keeps rising"] W["Whistleblowers +
WSJ reporting"] -->|"2015"| X["Collapse"]
  • Secrecy: Theranos avoided peer review and kept details hidden, citing trade secrets.
  • A board short on expertise: its board included former US cabinet officials and military leaders, but few people with laboratory medicine experience.
  • Investors who skipped diligence: some major investors didn't see independent validation of the technology.
  • Pressure on employees: whistleblowers, including Tyler Shultz and Erika Cheung, faced legal threats before the story came out.
Key takeaway: in software, shipping early and iterating is normal. In healthcare, finance and safety-critical fields, claiming capabilities you don't have isn't ambition, it's harm. The validation is the product.

Lessons for Founders and Investors

  • Separate vision from current capability in every claim you make
  • Invite independent validation, especially in regulated industries
  • Build a board and advisers with real domain expertise
  • Treat whistleblowers as signals, not threats
  • Investors: ask for data, not demos

Frequently Asked Questions

What was Theranos supposed to do?

Theranos claimed its Edison device could run a wide range of blood tests on a few drops of blood from a finger prick, faster and cheaper than traditional labs, with tests offered in retail pharmacies like Walgreens.

What happened to Elizabeth Holmes?

In January 2022, a jury convicted Elizabeth Holmes on four counts of defrauding investors. In November 2022, she was sentenced to more than 11 years in federal prison. Former Theranos president Ramesh Balwani was convicted separately on 12 counts.

How was Theranos exposed?

Wall Street Journal reporter John Carreyrou published an investigation in October 2015 based on information from former employees, who said the technology didn't work as claimed. Regulatory inspections, sanctions and lawsuits followed, and the company dissolved in 2018.

Conclusion

Theranos raised hundreds of millions and reached a $9 billion valuation on a promise its technology couldn't keep. Secrecy, a board without lab expertise and investors without proper diligence kept it going until whistleblowers and the Wall Street Journal exposed it. The lesson is simple: in fields where errors hurt people, proof has to come before scale.

Sources

Last verified: 2 November 2026.

Related reads: What Happened to Vine? · What Happened to BlackBerry? · Ship It or Kill It

I write about why tech companies win and lose. Follow on LinkedIn or X, or invite me to speak.